Etanercept Suppresses Arteritis in a Murine Model of Kawasaki Disease: A Comparative Study Involving Different Biological Agents
Table 1
Animal data. Body weight (BW), heart weight (HW), and HW/BW ratio (%) in each group at 2 and 4 weeks.
Con
CAWS
IVIG
EC
MP
CsA
2 weeks ( for each group)
Body weight (g)
21.7 ± 1.1
20.9 ± 0.1
19.2 ± 0.1
21.3 ± 0.1
19.7 ± 0.1
18.8 ± 0.1
Heart weight (g)
0.14 ± 0.04
0.13 ± 0.02
0.12 ± 0.02
0.13 ± 0.01
0.12 ± 0.01
0.12 ± 0.01
HW/BW (%)
0.62 ± 0.1
0.60 ± 0.06
0.60 ± 0.05
0.61 ± 0.04
0.59 ± 0.01
0.62 ± 0.08
4 weeks ( for each group)
Body weight (g)
22.2 ± 0.14
20.9 ± 0.2
22.8 ± 0.1
21.4 ± 0.1
19.5 ± 0.1
22.4 ± 0.1
Heart weight (g)
0.14 ± 0.01
0.18 ± 0.02
0.14 ± 0.02
0.15 ± 0.02
0.13 ± 0.01
0.13 ± 0.03
HW/BW (%)
0.63 ± 0.06
0.86 ± 0.07#
0.59 ± 0.07
0.68 ± 0.07
0.68 ± 0.05
0.57 ± 0.14
versus Con.
Abbreviations: control (Con), CAWS with no drug treatment (CAWS), immunoglobulin (IVIG), etanercept (EC), methylprednisolone (MP), and cyclosporine-A (CsA).
